‘Dozens’ of treatments for chronic itch under investigation

CLEVELAND — After more than a decade with no new medications for chronic spontaneous urticaria, clinicians are beginning to see rapid progress, according to a speaker at the Medical Dermatology Therapy Update IV. FDA approvals of the biologic dupilumab (Dupixent, Sanofi and Regeneron) and twice-daily oral therapy remibrutinib (Rhapsido, Novartis) for chronic spontaneous urticaria in 2025